论文部分内容阅读
进一步探讨拉米夫定相关性HBV变异对患者临床经过的影响。方法 将接受拉米夫定治疗10 0mg/d的 82例患者在第 10 4周按其发生变异程度分为完全变异 (F组 ,n =16)、部分变异 (M组 ,n =17)和无变异 (N组 ,n =4 9) 3组 ,分别进行肝功能和血清学指标比较。结果 在第 10 4周 ,F和M组无 1例HBcAg阴转 ,而N组有 18例( 3 6.7% )HBeAg阴转 ,11例 ( 2 2 .4 % )发生HBcAg/抗 HBe血清转换 ;拉米夫定相关性HBV变异发生后ALT可增高 ,完全变异组HBVDNA水平明显增高。结论 拉米夫定治疗 10 4周变异发生率为 4 0 .2 % ,变异发生后拉米夫定敏感性明显降低 ,从而影响疗效
To further explore the impact of lamivudine-related HBV mutation on clinical course. Methods Eighty-two patients treated with lamivudine at 10 mg / day were divided into complete mutation (F group, n = 16), partial mutation (M group, n = 17) No mutation (N group, n = 49) 3 groups, respectively, compared liver function and serological markers. Results In the 104th week, none of the F and M groups were negative for HBcAg, while in the N group, 18 cases (3. 6.7%) were negative for HBeAg and 11 cases (22.4%) had HBcAg / anti HBeAg seroconversion. ALT increased after lamivudine-associated HBV mutation, and HBV DNA level in complete mutation group increased significantly. Conclusions The incidence of 10-week variation in lamivudine treatment is 40.2%. The sensitivity of lamivudine after the mutation is significantly decreased, thus affecting the curative effect